AI-Driven Therapeutic Design
Designed,
Arka engineers drug candidates directly against disease targets — validated in silico in days, not years.
The Traditional Approach
- —Costly trial-and-error screening of compound libraries
- —90% of drug candidates fail before approval
- —Billions spent over multi-year R&D timelines
The Arka Platform
- →Molecules designed directly from disease targets
- →5-stage computational validation before any wet lab spend
- →Computational lead candidates in days, at a fraction of the cost
The Platform
How Arka
A fully computational drug discovery engine that replaces years of wet lab guesswork with targeted molecular design.
Inverse Design
Molecules engineered backwards from the target, not forward from a compound library.
Days, Not Years
Computational pipelines compress multi-year timelines into days of discovery.
5-Stage Validation
Binding affinity, selectivity, ADMET, resistance profile, and synthesis feasibility — all validated computationally.
Standard Hardware
No supercomputers or cloud infrastructure required to run our platform.
Days
From target to computational lead
0
Computational validation stages
0
Programs in pipeline
Illustrative: a designed candidate (teal) binding the conserved viral nucleoprotein pocket (navy).
Inverse Design
The target dictates
Conventional discovery screens millions of compounds and hopes one binds. Arka works backwards — we read the structure of the disease target, the conserved viral nucleoprotein, and engineer a candidate built to fit it.
- →Start from the target, not a compound library
- →Every candidate validated in silico before synthesis
- →One conserved binding site, many viral families
Programs
Drug Discovery
A proprietary pipeline held from discovery through development — Arka retains full ownership of every candidate, capturing the full value of each breakthrough.
Viral NP Program
Hantaviruses · Influenza A/B · Ebola & Marburg
Lead target: Andes virus — hemorrhagic fever, 40% fatality, no approved treatment.
Lead candidate identified
Oncology
Cancer-specific protein targets
Near-term · 12–24 months
Muscle Preservation
Myostatin (MSTN) inhibition for GLP-1 combination therapy
Near-term · 12–24 months
Neurodegeneration
Alzheimer's & Parkinson's, plus rare and orphan diseases
Long-term
Backed by
Incubated at
Arka is being built inside Emery Pharma's drug-development infrastructure, with senior scientific guidance from its founder.
Dr. Ron Najafi
Scientific Advisor
Founder & CEO of Emery Pharma; founder & former CEO of NovaBay Pharmaceuticals (NYSE: NBY). PhD in chemistry from UC Davis and inventor on 50+ patents, with three decades advancing therapeutics from discovery to market.